Published in Ann Transl Med on June 01, 2016
HMGB1 is negatively correlated with the development of endometrial carcinoma and prevents cancer cell invasion and metastasis by inhibiting the process of epithelial-to-mesenchymal transition. Onco Targets Ther (2017) 0.75
MicroRNA-200c inhibits epithelial-mesenchymal transition, invasion, and migration of lung cancer by targeting HMGB1. PLoS One (2017) 0.75
Association between HMGB1 and asthma: a literature review. Clin Mol Allergy (2017) 0.75
Cancer-related inflammation. Nature (2008) 34.21
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol (2005) 11.57
Cancer stem cells: an old idea--a paradigm shift. Cancer Res (2006) 9.76
The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med (2005) 6.86
Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature (2000) 6.70
Immunological aspects of cancer chemotherapy. Nat Rev Immunol (2008) 6.61
HMG domain proteins: architectural elements in the assembly of nucleoprotein structures. Trends Genet (1994) 5.43
Human T cell responses against melanoma. Annu Rev Immunol (2006) 4.99
The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat Genet (1999) 4.77
Inflammation and necrosis promote tumour growth. Nat Rev Immunol (2004) 3.68
Structural features of the HMG chromosomal proteins and their genes. Biochim Biophys Acta (1990) 3.55
The therapeutic promise of the cancer stem cell concept. J Clin Invest (2010) 3.26
Cancer: Inflaming metastasis. Nature (2009) 3.09
New EMBO members' review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal. EMBO J (2001) 3.04
HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep (2004) 3.00
The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev (2007) 2.96
Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med (2004) 2.94
Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res (2005) 2.91
Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis (2008) 2.89
HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med (2009) 2.56
Masquerader: high mobility group box-1 and cancer. Clin Cancer Res (2007) 2.40
High-mobility group box 1 (HMGB1) protein: friend and foe. Cytokine Growth Factor Rev (2006) 2.26
Substantial histone reduction modulates genomewide nucleosomal occupancy and global transcriptional output. PLoS Biol (2011) 2.26
Hydrogen peroxide stimulates macrophages and monocytes to actively release HMGB1. J Leukoc Biol (2006) 2.17
The distinctive nature of HER2-positive breast cancers. N Engl J Med (2005) 2.13
HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc Natl Acad Sci U S A (1994) 2.12
Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep (1980) 1.99
Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. Blood (2006) 1.82
Proteome analysis of soluble nuclear proteins reveals that HMGB1/2 suppress genotoxic stress in polyglutamine diseases. Nat Cell Biol (2007) 1.81
Chemotherapeutic approaches for targeting cell death pathways. Oncologist (2006) 1.70
Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res (2008) 1.69
Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia (2009) 1.66
Synthesis, characterization, and cytotoxicity of a series of estrogen-tethered platinum(IV) complexes. Chem Biol (2004) 1.66
The DNA-bending protein HMG-1 enhances progesterone receptor binding to its target DNA sequences. Mol Cell Biol (1994) 1.65
Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res (2002) 1.63
A pilot study to detect high mobility group box 1 and heat shock protein 72 in cerebrospinal fluid of pediatric patients with meningitis. Crit Care Med (2008) 1.62
Autophagy contributes to resistance of tumor cells to ionizing radiation. Radiother Oncol (2011) 1.54
Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin. Proc Natl Acad Sci U S A (2000) 1.46
High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J Immunother (2007) 1.45
Association of chromatin proteins high mobility group box (HMGB) 1 and HMGB2 with mitotic chromosomes. Mol Biol Cell (2003) 1.43
Efficient specific DNA binding by p53 requires both its central and C-terminal domains as revealed by studies with high-mobility group 1 protein. Mol Cell Biol (2002) 1.43
The isolation and purification of the high mobility group (HMG) nonhistone chromosomal proteins. Methods Cell Biol (1977) 1.38
Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1. Oncogene (2012) 1.37
HMGB1 is phosphorylated by classical protein kinase C and is secreted by a calcium-dependent mechanism. J Immunol (2009) 1.35
Implication of tumor microenvironment in chemoresistance: tumor-associated stromal cells protect tumor cells from cell death. Int J Mol Sci (2012) 1.32
HMG-1 stimulates estrogen response element binding by estrogen receptor from stably transfected HeLa cells. Mol Endocrinol (1999) 1.31
The expression of HMGB1 protein and its receptor RAGE in human malignant tumors. Mol Cell Biochem (2009) 1.31
Yeast Nhp6A/B and mammalian Hmgb1 facilitate the maintenance of genome stability. Curr Biol (2005) 1.24
HMGB1: a two-headed signal regulating tumor progression and immunity. Curr Opin Immunol (2008) 1.21
C-Myc-independent restoration of multiple phenotypes by two C-Myc target genes with overlapping functions. Cancer Res (2005) 1.19
Growth suppression and radiosensitivity increase by HMGB1 in breast cancer. Acta Pharmacol Sin (2007) 1.15
Cytolytic cells induce HMGB1 release from melanoma cell lines. J Leukoc Biol (2006) 1.14
DNA alkylating therapy induces tumor regression through an HMGB1-mediated activation of innate immunity. J Immunol (2011) 1.12
KLF4 promotes the expression, translocation, and releas eof HMGB1 in RAW264.7 macrophages in response to LPS. Shock (2008) 1.12
HMGB1 as a mediator of necrosis-induced inflammation and a therapeutic target in arthritis. Rheum Dis Clin North Am (2004) 1.09
Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer. Autophagy (2015) 1.04
Interactions between an HMG-1 protein and members of the Rel family. Proc Natl Acad Sci U S A (1999) 1.04
Variation of HMGB1 expression in breast cancer. Anticancer Res (2002) 1.04
Knockdown of HMGB1 in tumor cells attenuates their ability to induce regulatory T cells and uncovers naturally acquired CD8 T cell-dependent antitumor immunity. J Immunol (2011) 1.04
The expression of receptor for advanced glycation end products is associated with angiogenesis in human oral squamous cell carcinoma. Virchows Arch (2007) 1.03
High mobility group B proteins facilitate strong estrogen receptor binding to classical and half-site estrogen response elements and relax binding selectivity. Mol Endocrinol (2004) 1.01
Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy. Tumour Biol (2012) 1.01
High-mobility group (HMG) protein HMG-1 and TATA-binding protein-associated factor TAF(II)30 affect estrogen receptor-mediated transcriptional activation. Mol Endocrinol (1997) 1.01
Cancer-associated fibroblasts induce high mobility group box 1 and contribute to resistance to doxorubicin in breast cancer cells. BMC Cancer (2014) 1.01
Effects of chemoradiation on tumor-host interactions: the immunologic side. J Clin Oncol (2008) 1.00
The noninflammatory role of high mobility group box 1/Toll-like receptor 2 axis in the self-renewal of mammary cancer stem cells. FASEB J (2013) 0.99
HMGB1 conveys immunosuppressive characteristics on regulatory and conventional T cells. Int Immunol (2012) 0.96
Age-dependent change of HMGB1 and DNA double-strand break accumulation in mouse brain. Biochem Biophys Res Commun (2008) 0.95
Physical interaction of tumour suppressor p53/p73 with CCAAT-binding transcription factor 2 (CTF2) and differential regulation of human high-mobility group 1 (HMG1) gene expression. Biochem J (2003) 0.94
Apoptosis: molecular mechanisms and implications for cancer chemotherapy. Pharm World Sci (1997) 0.91
The active gene that encodes human high mobility group 1 protein (HMG1) contains introns and maps to chromosome 13. Genomics (1996) 0.90
The human HMGB1 promoter is modulated by a silencer and an enhancer-containing intron. Biochim Biophys Acta (2001) 0.87
Plasma HMGB-1 after the initial dose of epirubicin/docetaxel in cancer. Eur J Clin Invest (2013) 0.86
Downregulation of high mobility group box 1 modulates telomere homeostasis and increases the radiosensitivity of human breast cancer cells. Int J Oncol (2014) 0.86
Fibroblasts protect melanoma cells from the cytotoxic effects of doxorubicin. Tissue Eng Part A (2014) 0.85
High mobility group B1 and N1 (HMGB1 and HMGN1) are associated with tumor-infiltrating lymphocytes in HER2-positive breast cancers. Virchows Arch (2015) 0.84
mir-129-5p Attenuates Irradiation-Induced Autophagy and Decreases Radioresistance of Breast Cancer Cells by Targeting HMGB1. Med Sci Monit (2015) 0.81
[Enhancive effect of HMGB1 gene silence on adriamycin-induced apoptosis in K562/A02 drug resistance leukemia cells]. Zhonghua Xue Ye Xue Za Zhi (2008) 0.81
[Role of high mobility group box 1 in adriamycin-induced apoptosis in leukemia K562 cells]. Ai Zheng (2008) 0.80
miR-200c inhibits metastasis of breast cancer cells by targeting HMGB1. J Huazhong Univ Sci Technolog Med Sci (2014) 0.80
Active immunotherapy for mouse breast cancer with irradiated whole-cell vaccine expressing VEGFR2. Oncol Rep (2013) 0.79
Apicidin and docetaxel combination treatment drives CTCFL expression and HMGB1 release acting as potential antitumor immune response inducers in metastatic breast cancer cells. Neoplasia (2012) 0.79
Differences between HMG1 proteins isolated from normal and tumour cells. Biochim Biophys Acta (1987) 0.79
Effects of HMGB-1 overexpression on cell-cycle progression in MCF-7 cells. J Korean Med Sci (2004) 0.78
Quercetin protects necrotic insult and promotes apoptosis by attenuating the expression of RAGE and its ligand HMGB1 in human breast adenocarcinoma cells. IUBMB Life (2015) 0.77
Caveolin-1 functions as a key regulator of 17β-estradiol-mediated autophagy and apoptosis in BT474 breast cancer cells. Int J Mol Med (2014) 0.77